{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:02:00Z","timestamp":1791655320236,"version":"4.3.4"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2018SF-2475"],"award-info":[{"award-number":["TMA2018SF-2475"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05277-x","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:16:31Z","timestamp":1738404991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas"],"prefix":"10.1186","volume":"24","author":[{"given":"Enock J.","family":"Kessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally I.","family":"Olotu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"5277_CR1","first-page":"2024","volume-title":"addressing inequity in the global malaria response","author":"WHO. World malaria report","year":"2024","unstructured":"WHO. World malaria report. addressing inequity in the global malaria response. Geneva: World Health Organization; 2024. p. 2024."},{"key":"5277_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7: a025619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5277_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI21682","volume":"113","author":"NJ White","year":"2004","unstructured":"White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084\u201392.","journal-title":"J Clin Invest"},{"key":"5277_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000406","volume":"8","author":"PL Alonso","year":"2011","unstructured":"Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8: e1000406.","journal-title":"PLoS Med"},{"key":"5277_CR5","doi-asserted-by":"crossref","unstructured":"John R, Ephraim T, Andrew A. Reduced susceptibility to pyrethroid insecticide treated nets by the malaria vector Anopheles gambiae s.l. in western Uganda. Malar J. 2008;7:92.","DOI":"10.1186\/1475-2875-7-92"},{"key":"5277_CR6","doi-asserted-by":"crossref","unstructured":"Soma DD, Zogo B, Hien DFS, Hien AS, Kabor\u00e9 DA, Kientega M, et al. Insecticide resistance status of malaria vectors Anopheles gambiae (s.l.) of southwest Burkina Faso and residual efficacy of indoor residual spraying with microencapsulated pirimiphos-methyl insecticide. Parasit Vectors. 2021;14:58.","DOI":"10.1186\/s13071-020-04563-8"},{"key":"5277_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24:43\u201356.","journal-title":"Cell Host Microbe"},{"key":"5277_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.805482","volume":"11","author":"E Takashima","year":"2021","unstructured":"Takashima E, Tachibana M, Morita M, Nagaoka H, Kanoi BN, Tsuboi T. Identification of novel malaria transmission-blocking vaccine candidates. Front Cell Infect Microbiol. 2021;11: 805482.","journal-title":"Front Cell Infect Microbiol"},{"key":"5277_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0074-02762010000100001","volume":"105","author":"IV Coutinho-Abreu","year":"2010","unstructured":"Coutinho-Abreu IV, Ramalho-Ortigao M. Transmission blocking vaccines to control insect-borne diseases: a review. Mem Inst Oswaldo Cruz. 2010;105:1\u201312.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"5277_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0264-410X(98)00246-1","volume":"17","author":"RT Mahoney","year":"1999","unstructured":"Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine. 1999;17:646\u201352.","journal-title":"Vaccine"},{"key":"5277_CR11","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1016\/j.vaccine.2014.07.030","volume":"32","author":"JK Nunes","year":"2014","unstructured":"Nunes JK, Woods C, Carter T, Raphael T, Morin MJ, Diallo D, et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. Vaccine. 2014;32:5531\u20139.","journal-title":"Vaccine"},{"key":"5277_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s13063-019-3900-8","volume":"20","author":"H Nevens","year":"2019","unstructured":"Nevens H, Harrison J, Vrijens F, Verleye L, Stocquart N, Marynen E, et al. Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency. Trials. 2019;20:714.","journal-title":"Trials"},{"key":"5277_CR13","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1128\/IAI.00479-17","volume":"86","author":"DI Stanisic","year":"2018","unstructured":"Stanisic DI, McCarthy JS, Good MF. Controlled human malaria infection: applications, advances, and challenges. Infect Immun. 2018;86:e00479-e517.","journal-title":"Infect Immun"},{"key":"5277_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bioe.12781","volume":"34","author":"I Jao","year":"2020","unstructured":"Jao I, Marsh V, Che Chi P, Kapulu M, Hamaluba M, Molyneux S, et al. Deliberately infecting healthy volunteers with malaria parasites: perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study. Bioethics. 2020;34:819\u201332.","journal-title":"Bioethics"},{"key":"5277_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri2902","volume":"11","author":"RW Sauerwein","year":"2011","unstructured":"Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57\u201364.","journal-title":"Nat Rev Immunol"},{"key":"5277_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/jme.2003.004440","volume":"30","author":"T Hope","year":"2004","unstructured":"Hope T, McMillan J. Challenge studies of human volunteers: ethical issues. J Med Ethics. 2004;30:110\u20136.","journal-title":"J Med Ethics"},{"key":"5277_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12931-018-0784-1","volume":"19","author":"R Lambkin-Williams","year":"2018","unstructured":"Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS. The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respir Res. 2018;19:123.","journal-title":"Respir Res"},{"key":"5277_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/cid\/ciz842","volume":"71","author":"TJ Merkel","year":"2020","unstructured":"Merkel TJ. Toward a controlled human infection model of pertussis. Clin Infect Dis. 2020;71:412\u20134.","journal-title":"Clin Infect Dis"},{"key":"5277_CR19","doi-asserted-by":"crossref","unstructured":"Jamrozik E, Selgelid MJ. Human challenge studies in endemic settings: ethical and regulatory issues. Springer Nature; 2021.","DOI":"10.1007\/978-3-030-41480-1"},{"key":"5277_CR20","first-page":"263","volume":"3","author":"MJ Selgelid","year":"2018","unstructured":"Selgelid MJ, Jamrozik E. Ethical challenges posed by human infection challenge studies in endemic settings. Indian J Med Ethics. 2018;3:263\u20136.","journal-title":"Indian J Med Ethics"},{"key":"5277_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003591","volume":"18","author":"JM Chavatte","year":"2021","unstructured":"Chavatte JM, Snounou G. Controlled human malaria infection - maker and breaker of dogma. PLoS Med. 2021;18: e1003591.","journal-title":"PLoS Med"},{"key":"5277_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","volume":"15","author":"TC Darton","year":"2015","unstructured":"Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis. 2015;15:840\u201351.","journal-title":"Lancet Infect Dis"},{"key":"5277_CR23","doi-asserted-by":"publisher","first-page":"e01884","DOI":"10.1128\/AAC.01884-19","volume":"64","author":"J DeVincenzo","year":"2020","unstructured":"DeVincenzo J, Tait D, Efthimiou J, Mori J, Kim YI, Thomas E, et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob Agents Chemother. 2020;64:e01884-e1919.","journal-title":"Antimicrob Agents Chemother"},{"key":"5277_CR24","doi-asserted-by":"crossref","unstructured":"Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J Infect Dis. 2022;226:396\u2013406.","DOI":"10.1093\/infdis\/jiab003"},{"key":"5277_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","volume":"49","author":"S Balasingam","year":"2016","unstructured":"Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis. 2016;49:18\u201329.","journal-title":"Int J Infect Dis"},{"key":"5277_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1473-3099(21)00702-7","volume":"22","author":"TG Evans","year":"2022","unstructured":"Evans TG, Bussey L, Eagling-Vose E, Rutkowski K, Ellis C, Argent C, et al. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. Lancet Infect Dis. 2022;22:857\u201366.","journal-title":"Lancet Infect Dis"},{"key":"5277_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","volume":"28","author":"B Killingley","year":"2022","unstructured":"Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022;28:1031\u201341.","journal-title":"Nat Med"},{"key":"5277_CR28","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/infdis\/jiaa021","volume":"221","author":"VP Costantini","year":"2020","unstructured":"Costantini VP, Cooper EM, Hardaker HL, Lee LE, DeBess EE, Cieslak PR, et al. Humoral and mucosal immune responses to human norovirus in the elderly. J Infect Dis. 2020;221:1864\u201374.","journal-title":"J Infect Dis"},{"key":"5277_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121077","volume":"3","author":"L Kim","year":"2018","unstructured":"Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, et al. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018;3: e121077.","journal-title":"JCI Insight"},{"key":"5277_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/infdis\/jiu385","volume":"211","author":"AE Kirby","year":"2015","unstructured":"Kirby AE, Teunis PF, Moe CL. Two human challenge studies confirm high infectivity of Norwalk virus. J Infect Dis. 2015;211:166\u20137.","journal-title":"J Infect Dis"},{"key":"5277_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1128\/CVI.00608-15","volume":"23","author":"S Chakraborty","year":"2016","unstructured":"Chakraborty S, Harro C, DeNearing B, Bream J, Bauers N, Dally L, et al. Evaluation of the safety, tolerability, and immunogenicity of an oral, inactivated whole-cell Shigella flexneri 2a vaccine in healthy adult subjects. Clin Vaccine Immunol. 2016;23:315\u201325.","journal-title":"Clin Vaccine Immunol"},{"key":"5277_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103308","volume":"66","author":"KA Clarkson","year":"2021","unstructured":"Clarkson KA, Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer A, et al. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine. EBioMedicine. 2021;66: 103308.","journal-title":"EBioMedicine"},{"key":"5277_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101076","volume":"39","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck RW Jr, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, et al. Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine. 2021;39: 101076.","journal-title":"EClinicalMedicine"},{"key":"5277_CR34","first-page":"177","volume":"445","author":"MB Cohen","year":"2024","unstructured":"Cohen MB. Human challenge studies for cholera. Curr Top Microbiol Immunol. 2024;445:177\u201388.","journal-title":"Curr Top Microbiol Immunol"},{"key":"5277_CR35","doi-asserted-by":"crossref","unstructured":"Fakoya B, Hullahalli K, Rubin DHF, Leitner DR, Chilengi R, Sack DA, et al. Nontoxigenic Vibrio cholerae challenge strains for evaluating vaccine efficacy and inferring mechanisms of protection. mBio. 2022:e0053922.","DOI":"10.1101\/2021.12.17.473008"},{"key":"5277_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/cix042","volume":"64","author":"HC Dobinson","year":"2017","unstructured":"Dobinson HC, Gibani MM, Jones C, Thomaides-Brears HB, Voysey M, Darton TC, et al. Evaluation of the clinical and microbiological response to Salmonella Paratyphi A infection in the first paratyphoid human challenge model. Clin Infect Dis. 2017;64:1066\u201373.","journal-title":"Clin Infect Dis"},{"key":"5277_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/cid\/ciy670","volume":"68","author":"MM Gibani","year":"2019","unstructured":"Gibani MM, Voysey M, Jin C, Jones C, Thomaides-Brears H, Jones E, et al. The impact of vaccination and prior exposure on stool shedding of Salmonella typhi and Salmonella paratyphi in 6 controlled human infection studies. Clin Infect Dis. 2019;68:1265\u201373.","journal-title":"Clin Infect Dis"},{"key":"5277_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018594","volume":"7","author":"H de Graaf","year":"2017","unstructured":"de Graaf H, Gbesemete D, Gorringe AR, Diavatopoulos DA, Kester KE, Faust SN, et al. Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open. 2017;7: e018594.","journal-title":"BMJ Open"},{"key":"5277_CR39","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/cid\/civ098","volume":"60","author":"AM Deasy","year":"2015","unstructured":"Deasy AM, Guccione E, Dale AP, Andrews N, Evans CM, Bennett JS, et al. Nasal inoculation of the commensal Neisseria lactamica inhibits carriage of Neisseria meningitidis by young adults: a controlled human infection study. Clin Infect Dis. 2015;60:1512\u201320.","journal-title":"Clin Infect Dis"},{"key":"5277_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12879-021-06173-w","volume":"21","author":"LV Fabri","year":"2021","unstructured":"Fabri LV, Azzopardi KI, Osowicki J, Frost HR, Smeesters PR, Steer AC. An emm-type specific qPCR to track bacterial load during experimental human Streptococcus pyogenes pharyngitis. BMC Infect Dis. 2021;21:463.","journal-title":"BMC Infect Dis"},{"key":"5277_CR41","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/infdis\/jis012","volume":"205","author":"AM Minassian","year":"2012","unstructured":"Minassian AM, Satti I, Poulton ID, Meyer J, Hill AVS, McShane H. A Human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis Bacille Calmette-Gu\u00e9rin. J Infect Dis. 2012;205:1035\u201342.","journal-title":"J Infect Dis"},{"key":"5277_CR42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3201\/eid1004.030356","volume":"10","author":"EM Alfano-Sobsey","year":"2004","unstructured":"Alfano-Sobsey EM, Eberhard ML, Seed JR, Weber DJ, Won KY, Nace EK, et al. Human challenge pilot study with Cyclospora cayetanensis. Emerg Infect Dis. 2004;10:726\u20138.","journal-title":"Emerg Infect Dis"},{"key":"5277_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S1473-3099(21)00153-5","volume":"21","author":"PR Chapman","year":"2021","unstructured":"Chapman PR, Webster R, Giacomin P, Llewellyn S, Becker L, Pearson MS, et al. Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021;21:1725\u201336.","journal-title":"Lancet Infect Dis"},{"key":"5277_CR44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/infdis\/jiaa157","volume":"224","author":"M Alkema","year":"2021","unstructured":"Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert GJ, et al. A randomized clinical trial to compare Plasmodium falciparum gametocytemia and infectivity after blood-stage or mosquito bite-induced controlled malaria infection. J Infect Dis. 2021;224:1257\u201365.","journal-title":"J Infect Dis"},{"key":"5277_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31549","volume":"7","author":"IJ Reuling","year":"2018","unstructured":"Reuling IJ, van de Schans LA, Coffeng LE, Lanke K, Meerstein-Kessel L, Graumans W, et al. A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model. Elife. 2018;7: e31549.","journal-title":"Elife"},{"key":"5277_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR47","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4269\/ajtmh.2009.09-0194","volume":"81","author":"S Herrera","year":"2009","unstructured":"Herrera S, Fern\u00e1ndez O, Manzano MR, Murrain B, Vergara J, Blanco P, et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg. 2009;81:740\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR48","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jit394","volume":"208","author":"JS McCarthy","year":"2013","unstructured":"McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013;208:1688\u201394.","journal-title":"J Infect Dis"},{"key":"5277_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005139","volume":"10","author":"P Griffin","year":"2016","unstructured":"Griffin P, Pasay C, Elliott S, Sekuloski S, Sikulu M, Hugo L, et al. Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Negl Trop Dis. 2016;10: e0005139.","journal-title":"PLoS Negl Trop Dis"},{"key":"5277_CR50","first-page":"948","volume":"221","author":"J Woodford","year":"2020","unstructured":"Woodford J, Collins KA, Odedra A, Wang C, Jang IK, Domingo GJ, et al. An experimental human blood-stage model for studying Plasmodium malariae infection. J Infect Dis. 2020;221:948\u201355.","journal-title":"J Infect Dis"},{"key":"5277_CR51","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1086\/322664","volume":"33","author":"FG Miller","year":"2001","unstructured":"Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis. 2001;33:1028\u201333.","journal-title":"Clin Infect Dis"},{"key":"5277_CR52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/phe\/phv026","volume":"9","author":"B Bambery","year":"2016","unstructured":"Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics. 2016;9:92\u2013103.","journal-title":"Public Health Ethics"},{"key":"5277_CR53","first-page":"61","volume":"17","author":"EA Largent","year":"2017","unstructured":"Largent EA, Fernandez LH. Paying research participants: regulatory uncertainty, conceptual confusion, and a path forward. Yale J Health Policy Law Ethics. 2017;17:61\u2013141.","journal-title":"Yale J Health Policy Law Ethics"},{"key":"5277_CR54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1056\/NEJM199907153410312","volume":"341","author":"N Dickert","year":"1999","unstructured":"Dickert N, Grady C. What\u2019s the price of a research subject? Approaches to payment for research participation. N Engl J Med. 1999;341:198\u2013203.","journal-title":"N Engl J Med"},{"key":"5277_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018;99:338\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR56","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo SA, Church LWP, Mtoro AT, Schindler T, Chakravarty S, Ruben AJ, et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian Adults. Clin Infect Dis. 2020;71:2849\u201357.","journal-title":"Clin Infect Dis"},{"key":"5277_CR57","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1128\/IAI.03069-14","volume":"83","author":"JM Obiero","year":"2015","unstructured":"Obiero JM, Shekalaghe S, Hermsen CC, Mpina M, Bijker EM, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infect Immun. 2015;83:2185\u201396.","journal-title":"Infect Immun"},{"key":"5277_CR58","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3389\/fmicb.2014.00686","volume":"5","author":"SH Hodgson","year":"2014","unstructured":"Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.","journal-title":"Front Microbiol"},{"key":"5277_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146443","volume":"6","author":"MC Kapulu","year":"2021","unstructured":"Kapulu MC, Njuguna P, Hamaluba M, Kimani D, Ngoi JM, Musembi J, et al. Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. JCI Insight. 2021;6: e146443.","journal-title":"JCI Insight"},{"key":"5277_CR60","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/cid\/ciz740","volume":"70","author":"J Achan","year":"2020","unstructured":"Achan J, Reuling IJ, Yap XZ, Dabira E, Ahmad A, Cox M, et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a Plasmodium falciparum controlled human infection. Clin Infect Dis. 2020;70:2544\u201352.","journal-title":"Clin Infect Dis"},{"key":"5277_CR61","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","volume":"98","author":"B Lell","year":"2018","unstructured":"Lell B, Mordm\u00fcller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018;98:508\u201315.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR62","first-page":"9","volume":"18","author":"T Schindler","year":"2019","unstructured":"Schindler T, Robaina T, Sax J, Bieri JR, Mpina M, Gondwe L, et al. Molecular monitoring of the diversity of human pathogenic malaria species in blood donations on Bioko Island. Equatorial Guinea Malar J. 2019;18:9.","journal-title":"Equatorial Guinea Malar J"},{"key":"5277_CR63","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0264-410X(92)90347-M","volume":"10","author":"P Suntharasamai","year":"1992","unstructured":"Suntharasamai P, Migasena S, Vongsthongsri U, Supanaranond W, Pitisuttitham P, Supeeranan L, et al. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers. Vaccine. 1992;10:502\u20135.","journal-title":"Vaccine"},{"key":"5277_CR64","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","volume":"30","author":"L Bodhidatta","year":"2012","unstructured":"Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, et al. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine. 2012;30:7040\u20135.","journal-title":"Vaccine"},{"key":"5277_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/medethics-2019-106001","volume":"46","author":"E Jamrozik","year":"2020","unstructured":"Jamrozik E, Selgelid MJ. Human infection challenge studies in endemic settings and\/or low-income and middle-income countries: key points of ethical consensus and controversy. J Med Ethics. 2020;46:601\u20139.","journal-title":"J Med Ethics"},{"key":"5277_CR66","unstructured":"WHO. Hhuman challenge trials for vaccine development: regulatory considerations, Annex 10. WHO Technical Report Series. 2017;1004. Available from: https:\/\/www.who.int\/publications\/m\/item\/human-challenge-trials-for-vaccine-a10-trs-no-1004"},{"key":"5277_CR67","doi-asserted-by":"crossref","unstructured":"Kunda-Ng'andu EM, Simuyandi M, Kapulu M, Chirwa-Chobe M, Mwanyungwi-Chinganya H, Mwale S, et al. Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia. Wellcome Open Res. 2021;6:31.","DOI":"10.12688\/wellcomeopenres.16432.1"},{"key":"5277_CR68","first-page":"194","volume":"50","author":"HR Coatney","year":"1949","unstructured":"Coatney HR, Cooper WC, Ruhe DS, Young MD. Studies in human malaria;trials of quinacrine, colchicine (SN 12,080) and quinine against Chesson strain vivax malaria. Am J Hyg. 1949;50:194\u20139.","journal-title":"Am J Hyg"},{"key":"5277_CR69","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.pt.2012.09.001","volume":"28","author":"CR Engwerda","year":"2012","unstructured":"Engwerda CR, Minigo G, Amante FH, McCarthy JS. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515\u201321.","journal-title":"Trends Parasitol"},{"key":"5277_CR70","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000441-197312000-00001","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266:398\u2013403.","journal-title":"Am J Med Sci"},{"key":"5277_CR71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4269\/ajtmh.1975.24.397","volume":"24","author":"DF Clyde","year":"1975","unstructured":"Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975;24:397\u2013401.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR72","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2307\/3284083","volume":"82","author":"CL Morris","year":"1996","unstructured":"Morris CL, Sullivan JS, McClure HM, Strobert E, Richardson BB, Galland GG, et al. The Nigerian I\/CDC strain of Plasmodium ovale in chimpanzees. J Parasitol. 1996;82:444\u20138.","journal-title":"J Parasitol"},{"key":"5277_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.614122","volume":"10","author":"EM Pasini","year":"2020","unstructured":"Pasini EM, Kocken CHM. Parasite-host interaction and pathophysiology studies of the human relapsing malarias Plasmodium vivax and Plasmodium ovale infections in non-human primates. Front Cell Infect Microbiol. 2020;10: 614122.","journal-title":"Front Cell Infect Microbiol"},{"key":"5277_CR74","doi-asserted-by":"crossref","unstructured":"Muerhoff AS, Birkenmeyer LG, Coffey R, Dille BJ, Barnwell JW, Collins WE, et al. Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates. Clin Vaccine Immunol. 2010;17:1631\u20138.","DOI":"10.1128\/CVI.00196-10"},{"key":"5277_CR75","doi-asserted-by":"crossref","unstructured":"Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, Faber BW, et al. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT\u2122 protects against blood-stage challenge in rhesus macaques. PLoS One. 2011;6:e20547.","DOI":"10.1371\/journal.pone.0020547"},{"key":"5277_CR76","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/mt.2012.223","volume":"20","author":"SH Sheehy","year":"2012","unstructured":"Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20:2355\u201368.","journal-title":"Mol Ther"},{"key":"5277_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005254","volume":"4","author":"MD Spring","year":"2009","unstructured":"Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE. 2009;4: e5254.","journal-title":"PLoS ONE"},{"key":"5277_CR78","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"5277_CR79","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"5277_CR80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0035-9203(91)90012-N","volume":"85","author":"T Ponnudurai","year":"1991","unstructured":"Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans R Soc Trop Med Hyg. 1991;85:175\u201380.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5277_CR81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0035-9203(90)90258-G","volume":"84","author":"R Rosenberg","year":"1990","unstructured":"Rosenberg R, Wirtz RA, Schneider I, Burge R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg. 1990;84:209\u201312.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5277_CR82","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/427243","volume":"191","author":"P Bejon","year":"2005","unstructured":"Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis. 2005;191:619\u201326.","journal-title":"J Infect Dis"},{"key":"5277_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022271","volume":"6","author":"CJ Duncan","year":"2011","unstructured":"Duncan CJ, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1\/Alhydrogel+CPG 7909. PLoS ONE. 2011;6: e22271.","journal-title":"PLoS ONE"},{"key":"5277_CR84","doi-asserted-by":"crossref","unstructured":"Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1\/AS01. J Infect Dis. 2016;213:1743\u201351.","DOI":"10.1093\/infdis\/jiw039"},{"key":"5277_CR85","doi-asserted-by":"publisher","first-page":"878","DOI":"10.4269\/ajtmh.2008.78.878","volume":"78","author":"F Sanderson","year":"2008","unstructured":"Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg. 2008;78:878\u201383.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR86","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4269\/ajtmh.2012.11-0504","volume":"86","author":"CJ Duncan","year":"2012","unstructured":"Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012;86:561\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12936-021-03627-z","volume":"20","author":"SD Woolley","year":"2021","unstructured":"Woolley SD, Fernandez M, Rebelo M, Llewellyn SA, Marquart L, Amante FH, et al. Development and evaluation of a new Plasmodium falciparum 3D7 blood stage malaria cell bank for use in malaria volunteer infection studies. Malar J. 2021;20:93.","journal-title":"Malar J"},{"key":"5277_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103919","volume":"77","author":"M Alkema","year":"2022","unstructured":"Alkema M, Yap XZ, de Jong GM, Reuling IJ, de Mast Q, van Crevel R, et al. Controlled human malaria infections by mosquito bites induce more severe clinical symptoms than asexual blood-stage challenge infections. EBioMedicine. 2022;77: 103919.","journal-title":"EBioMedicine"},{"key":"5277_CR89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12936-015-0663-x","volume":"14","author":"DI Stanisic","year":"2015","unstructured":"Stanisic DI, Liu XQ, De SL, Batzloff MR, Forbes T, Davis CB, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J. 2015;14:143.","journal-title":"Malar J"},{"key":"5277_CR90","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/infdis\/jir033","volume":"203","author":"AD Douglas","year":"2011","unstructured":"Douglas AD, Andrews L, Draper SJ, Bojang K, Milligan P, Gilbert SC, et al. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis. 2011;203:1337\u201340.","journal-title":"J Infect Dis"},{"key":"5277_CR91","doi-asserted-by":"crossref","unstructured":"Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One. 2013;8:e65960.","DOI":"10.1371\/journal.pone.0065960"},{"key":"5277_CR92","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/73062","volume":"6","author":"R Carter","year":"2000","unstructured":"Carter R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria transmission-blocking vaccines\u2013how can their development be supported? Nat Med. 2000;6:241\u20134.","journal-title":"Nat Med"},{"key":"5277_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS Sctp","year":"2015","unstructured":"Sctp RTS. Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"5277_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001994","volume":"13","author":"R Gosling","year":"2016","unstructured":"Gosling R, von Seidlein L. The future of the RTS, S\/AS01 malaria vaccine: an alternative development plan. PLoS Med. 2016;13: e1001994.","journal-title":"PLoS Med"},{"key":"5277_CR95","doi-asserted-by":"crossref","unstructured":"Arora N, C Anbalagan L, Pannu AK. Towards eradication of malaria: is the WHO's RTS,S\/AS01 vaccination effective enough? Risk Manag Healthc Policy. 2021;14:1033\u20139.","DOI":"10.2147\/RMHP.S219294"},{"key":"5277_CR96","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nm.3083","volume":"19","author":"EM Riley","year":"2013","unstructured":"Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nat Med. 2013;19:168\u201378.","journal-title":"Nat Med"},{"key":"5277_CR97","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young African children. N Engl J Med. 2016;374:2519\u201329.","journal-title":"N Engl J Med"},{"key":"5277_CR98","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ou\u00e9draogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403:533\u201344.","journal-title":"Lancet"},{"key":"5277_CR99","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo MS, Natama HM, Som\u00e9 A, Bellamy D, Traor\u00e9 O, Rouamba T, et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect Dis. 2022;22:1728\u201336.","journal-title":"Lancet Infect Dis"},{"key":"5277_CR100","doi-asserted-by":"crossref","unstructured":"Doumbo O, Niar\u00e9 K, Healy S, Sagara I, Duffy P. Malaria transmission-blocking vaccines: present status and future perspectives. In: Manguin S, Dev V (eds.). Towards malaria elimination - a leap forwards. IntechOpen, 2018.","DOI":"10.5772\/intechopen.77241"},{"key":"5277_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2021.102525","volume":"87","author":"M Tachibana","year":"2022","unstructured":"Tachibana M, Takashima E, Morita M, Sattabongkot J, Ishino T, Culleton R, et al. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation. Parasitol Int. 2022;87: 102525.","journal-title":"Parasitol Int"},{"key":"5277_CR102","doi-asserted-by":"crossref","unstructured":"Huff CG, Marchbank DF, Shiroishi T. Changes in infectiousness of malarial gametocytes. II. Analysis of the possible causative factors. Exp Parasitol. 1958;7:399\u2013417.","DOI":"10.1016\/0014-4894(58)90036-5"},{"issue":"Suppl 3","key":"5277_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4269\/ajtmh.21-1326","volume":"107","author":"DC Kaslow","year":"2022","unstructured":"Kaslow DC. Efforts to develop Pfs25 vaccines. Am J Trop Med Hyg. 2022;107(Suppl 3):32\u20135.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 3","key":"5277_CR104","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4269\/ajtmh.21-1320","volume":"107","author":"RW Sauerwein","year":"2022","unstructured":"Sauerwein RW, Plieskatt J, Theisen M. 40 years of Pfs48\/45 research as a transmission-blocking vaccine target of Plasmodium falciparum malaria. Am J Trop Med Hyg. 2022;107(Suppl 3):22\u20136.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 3","key":"5277_CR105","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4269\/ajtmh.21-1325","volume":"107","author":"A Molina-Cruz","year":"2022","unstructured":"Molina-Cruz A, Barillas-Mury C. Pfs47 as a malaria transmission-blocking vaccine target. Am J Trop Med Hyg. 2022;107(Suppl 3):27\u201331.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 3","key":"5277_CR106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4269\/ajtmh.21-1337","volume":"107","author":"PE Duffy","year":"2022","unstructured":"Duffy PE. The virtues and vices of Pfs230: from vaccine concept to vaccine candidate. Am J Trop Med Hyg. 2022;107(Suppl 3):17\u201321.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002636","volume":"3","author":"Y Wu","year":"2008","unstructured":"Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE. 2008;3: e2636.","journal-title":"PLoS ONE"},{"key":"5277_CR108","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4103\/0971-5916.191927","volume":"143","author":"N Chaturvedi","year":"2016","unstructured":"Chaturvedi N, Bharti PK, Tiwari A, Singh N. Strategies & recent development of transmission-blocking vaccines against. Indian J Med Res. 2016;143:696\u2013711.","journal-title":"Indian J Med Res"},{"key":"5277_CR109","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2875-6-107","volume":"6","author":"K Miura","year":"2007","unstructured":"Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25\/Pvs25 is a direct and predictable function of antibody titer. Malar J. 2007;6:107.","journal-title":"Malar J"},{"key":"5277_CR110","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","volume":"16","author":"NJ White","year":"2017","unstructured":"White NJ. Malaria parasite clearance. Malar J. 2017;16:88.","journal-title":"Malar J"},{"key":"5277_CR111","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1017\/S0031182008000280","volume":"135","author":"A Saul","year":"2008","unstructured":"Saul A. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology. 2008;135:1497\u2013506.","journal-title":"Parasitology"},{"key":"5277_CR112","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.1016\/j.vaccine.2015.08.073","volume":"33","author":"RW Sauerwein","year":"2015","unstructured":"Sauerwein RW, Bousema T. Transmission blocking malaria vaccines: Assays and candidates in clinical development. Vaccine. 2015;33:7476\u201382.","journal-title":"Vaccine"},{"key":"5277_CR113","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/ncomms2840","volume":"4","author":"AM Blagborough","year":"2013","unstructured":"Blagborough AM, Churcher TS, Upton LM, Ghani AC, Gething PW, Sinden RE. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun. 2013;4:1812.","journal-title":"Nat Commun"},{"key":"5277_CR114","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1038\/srep03418","volume":"3","author":"WJ Stone","year":"2013","unstructured":"Stone WJ, Eldering M, van Gemert GJ, Lanke KH, Grignard L, van de Vegte-Bolmer MG, et al. The relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. Sci Rep. 2013;3:3418.","journal-title":"Sci Rep"},{"key":"5277_CR115","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI98012","volume":"128","author":"KA Collins","year":"2018","unstructured":"Collins KA, Wang CYT, Adams M, Mitchell H, Rampton M, Elliott S, et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. J Clin Invest. 2018;128:1551\u201362.","journal-title":"J Clin Invest"},{"key":"5277_CR116","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ijpara.2012.09.002","volume":"42","author":"TS Churcher","year":"2012","unstructured":"Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, et al. Measuring the blockade of malaria transmission\u2013an analysis of the Standard Membrane Feeding Assay. Int J Parasitol. 2012;42:1037\u201344.","journal-title":"Int J Parasitol"},{"key":"5277_CR117","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4269\/ajtmh.16-1000","volume":"97","author":"MB Coulibaly","year":"2017","unstructured":"Coulibaly MB, Gabriel EE, Sinaba Y, Sylla D, Sacko A, Sylla L, et al. Optimizing direct membrane and direct skin feeding assays for Plasmodium falciparum transmission-blocking vaccine trials in Bancoumana. Mali Am J Trop Med Hyg. 2017;97:719\u201325.","journal-title":"Mali Am J Trop Med Hyg"},{"key":"5277_CR118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4269\/ajtmh.2001.64.32","volume":"64","author":"HP Awono-Ambene","year":"2001","unstructured":"Awono-Ambene HP, Diawara L, Robert V. Comparison of direct and membrane feeding methods to infect Anopheles arabiensis with Plasmodium falciparum. Am J Trop Med Hyg. 2001;64:32\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"5277_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042821","volume":"7","author":"T Bousema","year":"2012","unstructured":"Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS ONE. 2012;7: e42821.","journal-title":"PLoS ONE"},{"key":"5277_CR120","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0020-7519(01)00222-3","volume":"31","author":"MK Bhattacharyya","year":"2001","unstructured":"Bhattacharyya MK, Kumar N. Effect of xanthurenic acid on infectivity of Plasmodium falciparum to Anopheles stephensi. Int J Parasitol. 2001;31:1129\u201333.","journal-title":"Int J Parasitol"},{"key":"5277_CR121","unstructured":"WHO. Review of malaria vaccine clinical development. Geneva, World Health Organization. 2024. Available from: https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/who-review-of-malaria-vaccine-clinical-development."},{"key":"5277_CR122","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12936-017-1959-9","volume":"16","author":"IJ Reuling","year":"2017","unstructured":"Reuling IJ, Stone WJR, van de Vegte-Bolmer M, van Gemert GJ, Siebelink-Stoter R, Graumans W, et al. Concentration of Plasmodium falciparum gametocytes in whole blood samples by magnetic cell sorting enhances parasite infection rates in mosquito feeding assays. Malar J. 2017;16:315.","journal-title":"Malar J"},{"key":"5277_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007368","volume":"14","author":"S Yao","year":"2018","unstructured":"Yao S, Hong CC, Ruiz-Narv\u00e1ez EA, Evans SS, Zhu Q, Schaefer BA, et al. Genetic ancestry and population differences in levels of inflammatory cytokines in women: Role for evolutionary selection and environmental factors. PLoS Genet. 2018;14: e1007368.","journal-title":"PLoS Genet"},{"key":"5277_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0169-4758(99)01608-7","volume":"16","author":"M Dyer","year":"2000","unstructured":"Dyer M, Day KP. Commitment to gametocytogenesis in Plasmodium falciparum. Parasitol Today. 2000;16:102\u20137.","journal-title":"Parasitol Today"},{"key":"5277_CR125","doi-asserted-by":"publisher","first-page":"16662","DOI":"10.1074\/jbc.M114.551549","volume":"289","author":"S Chaubey","year":"2014","unstructured":"Chaubey S, Grover M, Tatu U. Endoplasmic reticulum stress triggers gametocytogenesis in the malaria parasite. J Biol Chem. 2014;289:16662\u201374.","journal-title":"J Biol Chem"},{"key":"5277_CR126","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12936-024-05071-1","volume":"23","author":"WA Azmi","year":"2024","unstructured":"Azmi WA, Rizki AFM, Shidiq A, Djuardi Y, Artika IM, Siregar JE. Antimalarial drug sulfadoxine induces gametocytogenesis in Plasmodium berghei. Malar J. 2024;23:267.","journal-title":"Malar J"},{"key":"5277_CR127","doi-asserted-by":"crossref","unstructured":"American Committee of Medical Entomology; American Society of Tropical Medicine and Hygiene. Arthropod Containment Guidelines, Version 3.2. Vector Borne Zoonotic Dis. 2019;19:152\u201373.","DOI":"10.1089\/vbz.2018.2431"},{"key":"5277_CR128","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/vbz.2017.2192","volume":"18","author":"MM Quinlan","year":"2018","unstructured":"Quinlan MM, Mutunga JM, Diabat\u00e9 A, Namountougou M, Coulibaly MB, Sylla L, et al. Studies of transgenic mosquitoes in disease-endemic countries: preparation of containment facilities. Vector Borne Zoonotic Dis. 2018;18:21\u201330.","journal-title":"Vector Borne Zoonotic Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05277-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:16:46Z","timestamp":1738405006000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05277-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5277"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05277-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}